Logotype for Bausch Health Companies Inc

Bausch Health (BHC) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Bausch Health Companies Inc

Q3 2026 earnings summary

29 Oct, 2026

Executive summary

  • 14th consecutive quarter of revenue and Adjusted EBITDA growth excluding Bausch + Lomb; quarterly Adjusted EBITDA exceeded $1B for the first time.

  • Q3 revenue was $2.941B, up 10% reported and 8% organically; Adjusted EBITDA attributable to Bausch Health Companies Inc. rose 32% to $1.305B.

  • Strong first-nine-month results supported a second consecutive quarterly increase to FY 2026 guidance for revenue, Adjusted EBITDA and adjusted cash flow from operations excluding Bausch + Lomb.

Financial highlights

  • Q3 operating income was $983M versus $619M; GAAP net income attributable to shareholders was $436M, or $1.15 per diluted share, versus $179M, or $0.48.

  • Adjusted gross margin was 75%, up 230 bps; adjusted cash flow from operations was $782M, up $274M or 54%.

  • Consolidated cash provided by operating activities was $813M, up 101%; adjusted net income attributable to shareholders was $673M versus $434M.

  • Nine-month revenue rose 11% to $8.317B; a $1.426B Salix goodwill impairment contributed to a $729M net loss.

  • Excluding Bausch + Lomb, Q3 revenue was $1.566B, up 12%; adjusted cash flow from operations was $539M, up $192M.

Outlook and guidance

  • FY 2026 consolidated revenue guidance increased to $10.975B–$11.175B and Adjusted EBITDA guidance to $4.315B–$4.415B.

  • FY 2026 guidance excluding Bausch + Lomb: revenue $5.525B–$5.625B, Adjusted EBITDA $3.225B–$3.275B and adjusted cash flow from operations $1.600B–$1.675B.

  • Guidance excluding Bausch + Lomb implies midpoint growth of 8% for revenue, 13% for Adjusted EBITDA and 29% for adjusted cash flow from operations.

  • Bausch + Lomb FY 2026 guidance is revenue of $5.450B–$5.550B and Adjusted EBITDA of $1.090B–$1.140B.

  • Q4 XIFAXAN gross-to-net accruals for the 2027 Medicare price change are expected to reduce revenue growth by 800 bps and Adjusted EBITDA growth by 1,400 bps; inventory normalization may reduce growth by a further 300 and 500 bps, respectively.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Bausch Health